Cardiomyopathies

Article written and reviewed by Dr Luca Moretti

Cardiomyopathies are diseases of the myocardium in which a structural or functional abnormality is not sufficiently explained by coronary artery disease, arterial hypertension, valvular disease, or congenital heart disease of sufficient severity and duration to produce the observed condition by themselves. The contemporary definition is intentionally clinical and does not seek to distinguish a priori between "primary" and "secondary" forms, because a systemic disease, a genetic variant, and an acquired exposure may coexist in the same patient. The diagnostic task is first to describe the cardiac phenotype and subsequently reconstruct its cause, without mistaking morphology for etiology.

This approach has corrected a historical view that identified cardiomyopathies almost exclusively with overt hypertrophy, dilatation, or restriction. The availability of cardiac magnetic resonance, prolonged rhythm monitoring, and genetics has shown that disease may begin with non-ischemic scar, conduction abnormalities, or arrhythmias before macroscopic chamber changes appear. There are therefore preclinical phases and incomplete phenotypes in which conventional diagnostic thresholds are not yet met, but the individual cannot simply be considered healthy. The challenge is to assign the correct weight to these findings, avoiding both failure to recognize early disease and pathologizing variants without consequences.

The 2023 ESC system recognizes five main phenotypes: hypertrophic cardiomyopathy, dilated cardiomyopathy, non-dilated left ventricular cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and restrictive cardiomyopathy. Ventricular hypertrabeculation and isolated right ventricular dysfunction are regarded as morphological features to be interpreted in context, not autonomous diagnoses based on a single imaging ratio. This framework does not erase widely used clinical categories, such as the spectrum of left-dominant or biventricular arrhythmogenic cardiomyopathy, but requires them to be described through documentable findings followed by etiologic attribution. Nosology therefore remains a tool for organizing complexity, not a substitute for clinical reasoning.

Epidemiological estimates are influenced by incomplete penetrance, variable expressivity, and the fact that historical studies mainly identified symptomatic patients or those referred to specialist centers. Imaging-detectable hypertrophic cardiomyopathy affects approximately one in five hundred adults, whereas the frequency of potentially relevant sarcomeric variants is higher. For dilated cardiomyopathy, modern estimates that include undiagnosed disease and familial aggregation reach approximately one in two hundred and fifty people, values far higher than older administrative series. Arrhythmogenic and restrictive forms are rarer, but their impact is disproportionate because they may present with malignant arrhythmias or severe heart failure before an etiologic diagnosis is established.

Prevalence alone does not describe the clinical burden. A common but mild phenotype may generate fewer events than a rare disease with high arrhythmic penetrance, and referral cohorts tend to overestimate risk when they collect complex cases. Conversely, population screening based on imaging alone may include individuals with physiological adaptations or nonspecific abnormalities, diluting the apparent severity. A correct epidemiological interpretation must specify the population, age, ascertainment method, diagnostic thresholds, and whether genetic confirmation was present. This is particularly important when data are used to communicate prognosis to an individual patient.

The natural history is not linear. Some people maintain preserved function for decades, others develop progressive fibrosis before dilatation, and still others experience phases of remission and relapse related to pregnancy, arrhythmias, infections, toxic exposures, or treatment withdrawal. The phenotype may also change: hypertrophic cardiomyopathy may evolve toward systolic dysfunction, an initially left-dominant desmosomal disease may become biventricular, and a non-dilated hypokinetic form may subsequently acquire the appearance of dilated cardiomyopathy. The diagnosis must therefore be updated over time without erasing the history that preceded its current expression.

Pediatric epidemiology differs from that of adults not only in frequency, but also in the distribution of causes. Syndromic, metabolic, and neuromuscular forms account for a larger proportion in the first years of life, whereas some dominant genotypes show penetrance during adolescence or adulthood. Hospitalization-based registries overrepresent severe heart failure and infants, whereas family screening identifies milder stages. Comparing these data without specifying the ascertainment method can produce apparently contradictory estimates that actually refer to different populations.

Geographic and ancestral distribution reflect founder variants, consanguinity, exposures, and access to diagnosis. A variant that is rare in one population may be relatively common and well characterized in another, changing both its frequency and interpretation. Genetic databases historically biased toward individuals of European ancestry increase the risk of mistakenly classifying benign variants present elsewhere as rare. Diversity in reference populations is therefore a prerequisite for clinical accuracy, not merely a goal of scientific representation.

The disease burden includes years of life with limitation, hospitalizations, devices, advanced therapies, and screening of entire families. A substantial number of patients initially receive generic diagnoses of heart failure, hypertensive hypertrophy, or myocarditis, delaying etiologic characterization. This delay is particularly consequential for treatable causes and for relatives who remain unaware of their risk. Dedicated pathways reduce fragmentation among rhythm, heart-failure, imaging, pediatric, and genetics clinics.

Socioeconomic inequalities influence access to cardiac magnetic resonance, genetic testing, specific drugs, and high-volume centers. Even a correct diagnosis may fail to translate into benefit if the patient cannot attend follow-up, adhere to treatment, or reach a center for procedures. Prognosis observed in specialist cohorts is therefore not merely a biological property of the disease, but also the result of selection and access. High-quality management must include local coordination and not rely exclusively on occasional attendance at a referral center.

Etiology, genetics, pathogenesis, and pathophysiology

Inherited cardiomyopathies result from abnormalities of proteins involved in contraction, force transmission, cell-to-cell adhesion, nuclear stability, metabolism, and protein quality control. Classification by cellular compartment is useful but not absolute, because a single protein may participate in multiple functions and the same cellular pathway may be disrupted by different genes. The initial consequence is amplified by secondary responses including energetic stress, calcium dysregulation, neurohormonal activation, sterile inflammation, cell death, and matrix deposition. The clinical phenotype emerges from the interaction between the molecular defect, duration of exposure, and the myocardium's capacity to compensate.

In sarcomeric hypertrophic cardiomyopathy, variants in MYBPC3 and MYH7 account for the largest proportion of molecular diagnoses, followed by other genes with established evidence. Altered sarcomeric function increases the energetic cost of contraction, modifies calcium sensitivity, and activates hypertrophic programs that do not affect all segments uniformly. Cardiomyocyte disarray, matrix expansion, and remodeling of intramural arterioles impair relaxation and perfusion even in the absence of epicardial coronary artery disease. The resulting fibrosis represents both a marker of cumulative injury and a potential substrate for ventricular arrhythmias.

Dilated cardiomyopathy has the most heterogeneous genetic architecture. Truncating variants in TTN are the most common genetic cause, but the significance of a variant depends on its location in exons expressed in the heart and on compatibility with phenotype and segregation. LMNA, FLNC, DSP, RBM20, BAG3, PLN, DES, SCN5A, and many other genes can produce systolic dysfunction with different propensities for conduction disease, arrhythmias, or progression. Dilatation is a late consequence of contractile loss and increased wall stress, not necessarily the event that initiates the disease.

Variants in LMNA impair the nuclear lamina and are often associated with atrioventricular conduction disease, atrial and ventricular arrhythmias that may precede severe reduction in ejection fraction. Variants in FLNC, DSP, and PLN may produce non-ischemic scar and electrical risk disproportionate to the degree of dilatation, whereas RBM20 alters splicing of multiple cardiac transcripts and may cause early and aggressive forms. These associations do not permit deterministic prognostication, but they explain why ejection fraction alone is insufficient for some ICD decisions. Genotype, scar distribution, arrhythmias, and family history must be considered together.

In classic arrhythmogenic cardiomyopathy, desmosomal genes are frequently involved, particularly PKP2, DSP, DSG2, DSC2, and JUP. Loss of integrity of intercellular junctions makes tissue vulnerable to mechanical stress and promotes cardiomyocyte death with fibrous or fibrofatty replacement. Endurance exercise increases wall load, heart rate, and adrenergic stimulation, accelerating expression and progression in many carriers. The disease is not confined to the right ventricle: DSP, FLNC, and other genes may produce left-dominant or biventricular phenotypes with inflammatory episodes resembling myocarditis.

Inherited restrictive forms may result from sarcomeric, cytoskeletal, or desmin-related variants, but the same hemodynamic pattern occurs in many systemic diseases. Ventricular stiffness limits filling and makes diastolic pressure highly sensitive to small increases in volume; the atria dilate because of chronic exposure to high pressures and become sites of fibrillation and stasis. When restriction is due to amyloidosis, storage, or infiltration, the mechanism also includes microvascular injury, direct protein toxicity, or conduction abnormalities. Restrictive physiology describes how the heart fills, whereas the RCM phenotype requires walls of normal thickness according to the ESC classification.

Modes of transmission include autosomal dominant inheritance, autosomal recessive, X-linked, and mitochondrial inheritance. Dominant forms often show age-related penetrance, so a parent who is clinically normal at the time of the child's diagnosis may later develop signs. Recessive forms more often present in childhood and may be accompanied by metabolic or neuromuscular syndromes; X-linked diseases show different expression in males and females, but female carriers should not be considered invariably asymptomatic. Heteroplasmy and replicative segregation make prediction particularly complex in mitochondrial diseases.

Penetrance is the proportion of carriers who develop a recognizable phenotype, whereas expressivity describes variability in manifestations among those who express the disease. Both are age-dependent and may be modified by sex, blood pressure, obesity, physical activity, pregnancy, infections, toxic exposures, and additional common or rare genetic variants. Consequently, the presence of a causal variant does not establish when disease will appear or how severe it will be. Counseling must communicate this uncertainty without diminishing the value of the molecular result for screening and prevention.

Genetic testing should prioritize genes with a validated gene-disease relationship, because indiscriminately broad panels mainly increase the number of variants of uncertain significance. A variant is classified using population frequency, functional data, segregation, recurrence in affected cases, predictions, and the nature of the alteration, following international criteria and gene-specific specifications. The VUS category denotes insufficient evidence and cannot be converted into a diagnosis, used for predictive testing in relatives, or invoked as the sole justification for a device. Periodic reassessment is necessary because new evidence may reclassify the finding in either direction.

Among acquired causes, myocarditis includes infectious, immune-mediated, and toxic processes that may resolve, recur, or leave persistent scar. Injury depends not only on the presence of an agent, but also on the intensity and duration of the immune response, lesion distribution, and host susceptibility. Recurrent episodes in carriers of DSP variants may mimic viral myocarditis and instead represent the inflammatory expression of a genetic cardiomyopathy. This example shows why elevated troponin with edema on cardiac magnetic resonance does not by itself define the etiology.

Anthracyclines, HER2 inhibitors, some tyrosine kinase inhibitors, immunotherapies, and other cancer therapies may cause dysfunction through different mechanisms. Toxicity may be cumulative and irreversible, as often occurs with anthracycline injury, or predominantly functional and reversible, but these categories are not absolute. Age, pre-existing heart disease, radiotherapy, drug combinations, and genetic predisposition modify risk. Cardio-oncology surveillance aims to recognize subclinical changes in function and biomarkers before overt heart failure develops.

Alcohol may exert direct toxicity through acetaldehyde, oxidative stress, mitochondrial abnormalities, and impaired protein synthesis, while also acting indirectly through hypertension, arrhythmias, and nutritional deficiencies. No individual threshold can prove causality, and history, duration, amount, recovery with abstinence, and the presence of other causes must be considered together. A truncating TTN variant is found in a proportion of forms attributed to alcohol, supporting a susceptibility model. Abstinence remains essential when alcohol use is considered causal or aggravating, but it does not replace heart-failure therapy.

Cardiomyopathy induced by tachycardia or a high premature ventricular contraction burden results from neurohormonal activation, altered calcium handling, inefficient energy use, and remodeling caused by a persistent rhythm disturbance. Diagnosis is often retrospective, supported by improvement after effective arrhythmia control, but the extent and timing of recovery vary. Tachycardia may be the cause, consequence, or simply a companion of structural cardiomyopathy, and persistent scar or a pathogenic genotype reduces the likelihood of complete reversibility. Arrhythmia recurrence may cause renewed deterioration more rapidly than the initial episode.

Peripartum cardiomyopathy occurs toward the end of pregnancy or in the following months in the absence of another explanation for dysfunction. Hemodynamic stress, angiogenic imbalance, prolactin fragments, inflammation, and genetic predisposition are proposed mechanisms, with a proportion of variants shared with dilated cardiomyopathy. Recovery is possible but not guaranteed, and normalization of ejection fraction does not completely abolish the risk of recurrence in subsequent pregnancies. Reproductive decisions require specialist assessment integrating residual function, clinical history, and the patient's preferences.

Infiltrative and storage diseases alter the myocardium through different processes. In amyloidosis, extracellular fibrils increase stiffness and impair microcirculation and conduction; in Fabry disease, glycosphingolipids accumulate within cells and trigger inflammation and fibrosis; in hemochromatosis, intracellular iron damages organelles and ion currents; in glycogen storage diseases, accumulation and metabolic signaling produce hypertrophy and pre-excitation in some phenotypes. Morphological similarity does not justify a common therapy, because each mechanism requires its own diagnostic evidence and treatment.

Regardless of cause, remodeling alters the coupling between mechanics and electrophysiology. Fibrosis interrupts conduction continuity, creates areas of slow propagation, and promotes reentry; dilatation increases wall tension and valvular regurgitation; hypertrophy reduces coronary reserve and distensibility; loss of synchrony worsens efficiency and oxygen consumption. Sympathetic activation and the renin-angiotensin system initially compensate for cardiac output but, when persistent, worsen cell death, sodium and water retention, and progression. Heart-failure therapy exploits precisely the possibility of interrupting these maladaptive circuits.

Titin links the sarcomere to the Z-discs and contributes to passive tension, assembly, and mechanosignaling. A truncating variant does not have the same effect at every location in the gene: the proportion of cardiac transcripts that include the exon, the efficiency of RNA degradation, and the presence of additional stressors modify the probability that the defect will become clinically manifest. This complexity explains why TTN variants may also be found in unselected populations and must be interpreted using specific criteria. When pathogenic, they may remain compensated until pregnancy, alcohol, tachycardia, or cardiotoxic agents reduce contractile reserve.

Cytoskeletal proteins convert sarcomeric force into cell movement and distribute stress to the membrane and matrix. Defects in desmin, filamin C, and dystrophin make the cardiomyocyte vulnerable to repeated contraction and link cardiomyopathy, conduction disease, and skeletal myopathy. The nuclear envelope participates in the same network: loss of integrity due to LMNA alters mechanotransduction, chromatin organization, and cell survival. The clinical result may be an early electrical phenotype, because the conduction system is affected by injury before contractile mass is reduced enough to dilate the ventricle.

The desmosome is not merely a mechanical rivet. Its proteins interact with signaling pathways that regulate cell identity, inflammation, and matrix deposition; their disruption facilitates detachment, death, and fibrotic repair in areas exposed to greater stress. In DSP-related forms, episodes with pain, troponin elevation, and edema may accompany new scars and indicate an active phase of disease. Repetition of these events progressively builds an electrical substrate, so that arrhythmias and dysfunction are not independent complications but different expressions of the same tissue process.

Mitochondrial diseases impair ATP production, redox balance, and calcium handling in an organ with continuous energy demand. Heteroplasmy produces a variable proportion of altered mitochondrial DNA among tissues and even among cells within the same organ, weakening the correlation between blood results and cardiac involvement. Phenotypes may be hypertrophic, dilated, or noncompaction and may be associated with deafness, diabetes, encephalopathy, myopathy, or conduction disorders. Maternal inheritance guides pedigree interpretation, but nuclear variants regulating mitochondria may follow Mendelian inheritance.

Proteostasis and autophagy control protein synthesis, folding, and degradation. Lysosomal storage diseases, chaperone defects, and variants promoting aggregation can fill cardiomyocytes with material, disrupt organelles, and activate inflammatory responses. The resulting hypertrophy does not merely represent an increase in contractile myofibrils and may be associated with unusual voltages, pre-excitation, or systemic manifestations not typical of sarcomeric HCM. Molecular characterization is therefore necessary to distinguish adaptive cardiomyocyte enlargement from potentially treatable storage.

The extracellular matrix is an active component of pathophysiology. Fibroblasts, myofibroblasts, macrophages, and signals derived from injured cardiomyocytes regulate the amount and organization of collagen, altering stiffness and conduction. Diffuse interstitial fibrosis raises filling pressures before a macroscopic scar appears, whereas replacement fibrosis marks irreversible cell loss. Cross-linking enzymes, matrix degradation, and mechanical tension determine whether remodeling can regress or becomes self-perpetuating.

The microcirculation contributes to progression even in the absence of epicardial stenoses. Hypertrophy, capillary rarefaction, arteriolar remodeling, edema, and increased intramural pressure reduce coronary reserve; in dilated cardiomyopathy, low perfusion pressure and high wall tension produce a similar imbalance. Recurrent ischemia worsens relaxation, promotes arrhythmias, and favors cell death. Myocardial perfusion should therefore be considered a property of the relationship among demand, microvessels, and hemodynamic conditions, not merely a consequence of coronary artery disease.

Age and biological sex modify penetrance and disease trajectory through hormones, body composition, blood pressure, exposures, and differences in myocardial response. Some dilated cardiomyopathy genotypes present on average earlier in males, whereas women may receive a later diagnosis despite significant symptoms and develop specific vulnerabilities during pregnancy. These associations are probabilistic and do not justify surveillance based on sex alone. Rather, they help interpret a carrier who is still phenotype-negative and prevent underdiagnosis caused by inadequately indexed dimensional reference values.

The immune response may be primary, secondary, or both. In viral myocarditis, pathogen recognition and cytotoxic injury may persist beyond the infectious phase; in autoimmune forms, antibodies and lymphocytes target cardiac structures; in genetic cardiomyopathies, injured cells release signals that recruit sterile inflammation. The same imaging appearance of edema may therefore arise from different mechanisms. Distinction requires timing, context, possible histology, and etiologic investigation, because antivirals, immunosuppression, and supportive therapy alone are not interchangeable strategies.

The genetic architecture is not always monogenic. Common variants distributed across the genome may increase or decrease the probability that a rare variant will be expressed and contribute to forms in which no single gene explains the phenotype. In HCM and DCM, association studies show alleles with opposing effects on mass, contractility, and risk, providing a partial explanation for variability. Polygenic scores are not yet universal tools for individual management and must be validated in diverse populations before influencing screening or device decisions.

De novo variants and mosaicism complicate pedigree interpretation. A variant arising in the proband causes genetic disease despite clinically and molecularly negative parents and may be transmitted to the next generation; parental germline mosaicism preserves a recurrence risk that is not always detectable in blood. Somatic mosaicism in the proband may produce a reduced variant allele fraction and escape low-depth platforms. These possibilities are considered when the phenotype is highly convincing but familial segregation appears atypical.

Mechanotransduction and epigenetics connect environment and genome. Pressure, volume, heart rate, and stress modify the activity of transcription factors, microRNAs, chromatin, and metabolism, stabilizing programs that were initially adaptive. Some of these changes regress when the load is removed, whereas fibrosis and cell loss make the change permanent. This continuum explains why the same exposure may produce adaptation in one individual and cardiomyopathy in another with lower genetic reserve.

Pathology, phenotypes, and natural history

Gross examination may show a dilated globular heart, marked asymmetric hypertrophy, small cavities with massively enlarged atria, or nearly normal dimensions despite diffuse scar. These appearances represent the end result of different processes and are not always recognizable in early stages. Pathology must be correlated with heart weight, wall measurements, lesion distribution, coronary arteries, valves, and the conduction system. In cases of sudden death, standardized autopsy examination and preservation of material for genetic investigations are essential because of the potential benefit to relatives.

In hypertrophic cardiomyopathy, the septum may be disproportionately thick relative to the free wall, but apical, concentric, and focal forms are also possible. Cardiomyocyte disarray, cellular hypertrophy, and interstitial fibrosis are characteristic but not exclusive findings, while thickening and narrowing of intramural arterioles contribute to ischemia. Repeated contact of the mitral leaflet with the septum may produce an endocardial fibrous plaque in the outflow tract. The correlation between the degree of disarray in a small biopsy sample and clinical risk is not sufficiently reliable to justify routine biopsies.

Dilated cardiomyopathy is characterized by increased volumes, relative wall thinning, and often mitral and tricuspid annular dilatation. Microscopically, compensatory myocyte hypertrophy, cell loss, and interstitial or replacement fibrosis predominate, findings that cannot by themselves define the cause. Scar distribution on cardiac magnetic resonance may provide information that globally unsampled histology captures less effectively: a septal mid-wall pattern is common in dilated cardiomyopathy, whereas ring-like subepicardial involvement may suggest DSP. Reverse remodeling with therapy demonstrates that chamber size and function are not necessarily irreversible outcomes.

In arrhythmogenic cardiomyopathy, fibrous or fibrofatty replacement often progresses from the epicardium toward the endocardium and may be regional in early stages. The right ventricle develops aneurysms, dyskinesia, and dilatation, whereas in left-dominant forms the wall may remain nearly normal in thickness despite extensive subepicardial scar. The absence of visible fat does not exclude the disease, and epicardial or intramyocardial fat physiologically increases with age and obesity. Pathological diagnosis therefore requires quantitative criteria and a consistent distribution, not a simple description of adiposity.

The non-dilated left ventricular phenotype encompasses two situations: non-ischemic scar or fatty replacement without dilatation, and isolated global hypokinesia. This grouping makes it possible to describe patients previously classified as healed myocarditis, early dilated cardiomyopathy, or left-dominant arrhythmogenic cardiomyopathy without uniform terminology. Natural history depends on the cause: some scars remain stable, whereas others extend or precede dysfunction and arrhythmias. The presence of LGE should nevertheless not automatically be equated with genetic disease, because ischemia, inflammation, and systemic conditions must be appropriately excluded.

Restrictive cardiomyopathy is characterized by non-dilated ventricular cavities, enlarged atria, and normal wall thickness, while the endocardium may be involved in endomyocardial forms. Endomyocardial fibrosis and hypereosinophilic syndrome may cause apical obliteration, thrombosis, and entrapment of the subvalvular apparatus, with atrioventricular regurgitation. In genetic forms, morphology may appear nonspecific despite very high filling pressures. The principal differential diagnosis is constrictive pericarditis, in which the impediment lies outside the myocardium and may be surgically correctable.

Hypertrabeculation describes an increase in trabeculae and recesses, most evident at the apex and lateral walls. Echocardiographic and cardiac magnetic resonance criteria are sensitive to loading conditions and may be met by people without cardiomyopathy, including pregnant women and athletes. Dysfunction, scar, arrhythmias, thrombi, an associated syndrome, or familial evidence are needed to assign pathological significance, and the finding must be integrated into the overall phenotype. The definition of "noncompaction" as a universal embryological arrest has not been demonstrated for all adult presentations.

The natural history can be schematically divided into a predisposition phase, a subclinical phase, and a phenotypic phase, but the boundaries are permeable. In genotype-positive, phenotype-negative carriers, ECG abnormalities, reduced strain, or LGE may appear before classic thresholds are met; however, not every variation inevitably anticipates overt disease. After phenotypic expression, the course may be stable, slowly progressive, or characterized by acute episodes. Inflammatory events, pregnancy, toxic exposure, and exercise burden may alter the slope of progression.

Reverse remodeling consists of reduced chamber volumes and improved function after treatment or removal of a causal factor. It is common in some dilated cardiomyopathies, tachycardia-induced cardiomyopathies, and after heart-failure therapy, but does not necessarily mean that the disease has disappeared. Scar, genetic susceptibility, and molecular abnormalities may persist despite a normalized ejection fraction. Relapse after treatment withdrawal observed in the TRED-HF study confirms that the term remission is often more appropriate than cure.

At the opposite extreme, progression leads to dilatation, increased filling pressures, functional valvular regurgitation, arrhythmias, and organ injury. In HCM, a minority develops a phase with ejection fraction below 50%, wall thinning, and variable dilatation; simply labeling this as new DCM erases the etiology and preceding history. In restrictive forms, systolic function may remain apparently preserved until an advanced stage while cardiac output and exercise tolerance progressively decline. The timing of referral for advanced therapies must take these specific trajectories into account.

Fibrosis takes different histological and topographic forms. Increased interstitial collagen separates groups of myocytes and contributes to stiffness, perivascular fibrosis accompanies small-vessel remodeling, and replacement fibrosis occupies areas of necrosis or apoptosis. A compact scar is more readily visible as LGE, whereas diffuse interstitial expansion may require T1 mapping and extracellular volume assessment. No noninvasive technique perfectly reproduces histology, but a biopsy sample of a few millimeters does not represent a heterogeneous whole-heart process any better.

The scar pattern helps distinguish mechanisms. A subendocardial distribution follows ischemic vulnerability and coronary territories, whereas mid-wall or subepicardial lesions suggest a non-ischemic origin. This rule has exceptions: embolism, vasospasm, sarcoidosis, and myocarditis may produce atypical appearances, and cardiomyopathy may coexist with myocardial infarction. Pathology should therefore be read as a probability map linked to the clinical history, not as an infallible etiologic signature.

Remodeling also involves the microcirculation and lymphatic system. Arteriolar thickening, a reduced capillary-to-mass ratio, and interstitial edema alter oxygen diffusion and tissue pressure. In infiltrative diseases, extracellular deposition or inflammatory cells further compress vessels and myocytes; in iron overload, injury is predominantly intracellular but likewise produces late fibrosis. These differences explain why hearts with similar wall thickness may show profoundly different perfusion, T1 values, and therapeutic responses.

The atria develop their own myopathy through pressure overload, stretch, inflammation, and genetic variants also expressed in atrial tissue. Dilatation and fibrosis impair reservoir, conduit, and pump function and create the substrate for atrial fibrillation, sometimes before severe ventricular abnormalities occur. A large atrium is therefore not merely a retrospective marker of filling pressures, but an organ that contributes to symptoms and thromboembolism. Ventricular recovery does not guarantee complete regression of atrial remodeling.

The right ventricle responds to afterload, ventricular interdependence, and primary involvement. In DCM it may dilate because of disease extension or pulmonary hypertension; in RCM it is affected early by high filling pressures and limited distensibility; in ARVC it is the principal target of the disease process. Its thin wall makes histological and imaging assessment more difficult and amplifies the effects of small pressure changes. Right ventricular function and tricuspid regurgitation have prognostic value that is not captured by left ventricular ejection fraction alone.

Valves and the subvalvular apparatus may be secondarily involved or may form an integral part of the phenotype. In dilated cardiomyopathy, papillary displacement and annular dilatation produce tethering; in HCM, leaflet elongation and papillary abnormalities favor systolic anterior motion; in endomyocardial diseases, fibrosis may incorporate chordae and muscles. Distinguishing a primary lesion from a consequence of ventricular disease is essential because repairing the valve without correcting the ventricular mechanism may be ineffective. Surgical anatomy often adds information that standard measurements alone cannot provide.

The conduction system may show fibrosis, infiltration, or cell loss disproportionate to the contractile myocardium. Laminopathies, sarcoidosis, amyloidosis, and muscular dystrophies may therefore present with atrioventricular block or nodal disease before heart failure. At autopsy, examination of the conduction system requires specialized techniques and is rarely performed completely, limiting explanation of some sudden bradyarrhythmic deaths. During life, serial progression of PR and QRS intervals provides a clinically relevant surrogate.

Pediatric age is associated with more extreme phenotypes and a higher relative frequency of syndromes, metabolic disorders, and neuromuscular diseases. A hypertrophied heart in a newborn may progress rapidly or regress after correction of a maternal condition, whereas post-myocarditis dilated cardiomyopathy may recover or require transplantation within a short period. Growth and maturation change dimensions, gene expression, and reserve, making pediatric reference standards necessary for interpretation of every finding. Natural history derived from adults cannot be transferred without adaptation.

Clinical manifestations

Many cardiomyopathies are diagnosed before symptoms arise following detection of a murmur, an abnormal electrocardiogram, imaging performed for another reason, or family screening. This mode of presentation does not imply benign disease: it may provide an opportunity to prevent complications before they occur, but requires risk estimation proportionate to the findings. An asymptomatic patient does not benefit from a label without practical consequences or from multiplication of tests without a precise question. Evaluation must clarify whether disease is present, what the plausible cause is, and what surveillance may modify the outcome.

Exertional dyspnea arises from mechanisms that often coexist: inadequate increase in cardiac output, elevated filling pressures, valvular regurgitation, dynamic obstruction, chronotropic incompetence, and abnormalities of the pulmonary circulation. The symptom may be underestimated because the patient gradually reduces activity and does not perceive a distinct change. Functional history should therefore refer to specific activities, temporal course, and comparison with peers, rather than simply asking whether breathlessness is present. Cardiopulmonary exercise testing allows better distinction among circulatory limitation, ventilatory limitation, and deconditioning.

Orthopnea and paroxysmal nocturnal dyspnea reflect increased pulmonary venous pressures, whereas edema and ascites indicate systemic congestion, often aggravated by tricuspid regurgitation or right ventricular dysfunction. In restrictive forms, congestion may be marked despite small ventricles and preserved ejection fraction, creating a false impression of normal function. In advanced dilated cardiomyopathy, signs of low output, hypotension, cold extremities, confusion, and worsening renal function identify a phase with an unfavorable prognosis. Body weight and jugular venous pressure are simple but useful tools for following the response to diuretics.

Palpitations may correspond to premature beats, supraventricular tachycardias, atrial fibrillation, or ventricular arrhythmias, but perception varies and does not quantify risk. Rapid atrial fibrillation is particularly poorly tolerated when filling depends on atrial contraction or the ventricle is stiff; loss of atrial systole may precipitate pulmonary edema in HCM, RCM, and amyloidosis. Conversely, clinically important ventricular arrhythmias may be asymptomatic and discovered on monitoring. Symptoms and rhythm must be correlated without assuming that lack of perception is equivalent to absence of arrhythmia.

Syncope requires differentiation among arrhythmic, hemodynamic, and reflex causes. A sudden episode without prodrome, during exertion or while supine, associated with trauma or a family history of sudden death increases suspicion of an arrhythmic cause; prolonged autonomic prodromes and situational triggers suggest a reflex mechanism, without excluding concomitant heart disease. In HCM, obstruction and an inadequate blood-pressure response may contribute, whereas advanced block is a specific possibility in laminopathies. The prognostic significance of syncope depends on the likelihood that it is cardiac and on its temporal proximity, not merely on its presence in the remote history.

Chest pain in cardiomyopathies may arise from mismatch between demand and perfusion, compression of intramural arterioles, increased wall stress, inflammation, or coexisting coronary artery disease. In HCM, microvascular ischemia may cause angina and scar despite normal epicardial coronary arteries; in inflammatory forms, pain may accompany a myopericarditis-like syndrome; in dilated cardiomyopathy, wall tension and low perfusion pressure may reduce reserve. Age and atherosclerotic profile nevertheless determine when coronary arteries need to be investigated. Attributing every episode of pain to cardiomyopathy risks missing a treatable coronary syndrome.

Conduction disorders may precede heart failure in laminopathies, sarcoidosis, Lyme disease, myotonic dystrophies, and some storage diseases. Advanced atrioventricular block in a relatively young adult should not be treated solely with a pacemaker without investigating its cause, because scar or an arrhythmogenic genotype may change device selection. Likewise, early atrial fibrillation may be the first sign of familial atrial and ventricular disease. Serial electrocardiograms document this evolution better than a single tracing.

Sudden cardiac death may be the first manifestation, especially in young people with unrecognized disease, but absolute risk varies widely. Mechanisms include ventricular tachycardia or fibrillation, advanced block, and, less commonly, acute hemodynamic deterioration. Careful autopsy, toxicology, and preservation of blood or tissue for genetic analysis enable postmortem diagnosis and initiation of family screening. The so-called molecular autopsy does not replace clinical evaluation of relatives and may identify uncertain variants requiring multidisciplinary interpretation.

Extracardiac manifestations narrow the differential diagnosis. Proximal weakness, contractures, or pseudohypertrophy suggest muscular dystrophies; neuropathy and dysautonomia may accompany ATTR amyloidosis; angiokeratomas, neuropathic pain, and nephropathy suggest Fabry disease; hearing loss, diabetes, and neurological disorders may indicate mitochondrial disease. An apparently isolated cardiac phenotype may precede other signs or predominate in adulthood. Examination should therefore include targeted assessment and not be confined to the cardiovascular system.

An acute presentation with pain, ST-segment elevation or depression, troponin elevation, and dysfunction may mimic an acute coronary syndrome. Coronary angiography or CCTA excludes epicardial obstruction when indicated, but the next step must distinguish myocarditis, takotsubo syndrome, sarcoidosis, and an acute flare of genetic cardiomyopathy. Edema and non-ischemic LGE support myocardial injury without automatically identifying its cause. Hemodynamic stability, arrhythmias, and the speed of deterioration determine the need for hospitalization, biopsy, or intensive support.

In children, symptoms may be nonspecific and appear as feeding difficulty, tachypnea, sweating, poor growth, or irritability, whereas older children may report reduced performance, pain, or syncope. Hepatomegaly may precede obvious edema, and the physiologically higher heart rate makes pathological tachycardia less immediately recognizable. School and sports provide useful observations of functional capacity. The threshold for referral to a pediatric center should be low when there is a family history, a syndrome, or neuromuscular disease.

Pregnancy may reveal pre-existing cardiomyopathy because of increased volume, heart rate, and cardiac output, or may be the setting of peripartum cardiomyopathy. Physiological dyspnea and edema make early disease difficult to distinguish, but orthopnea, pain, syncope, hypoxemia, a third heart sound, or disproportionately elevated natriuretic peptides require evaluation. The postpartum period is particularly delicate because of fluid redistribution. A diagnosis made during pregnancy should remain open until genetic, valvular, ischemic, and thromboembolic causes have been excluded.

In athletes, bradycardia, enlarged chambers, moderate wall thickening, and trabeculation may represent physiological adaptations. Exertional symptoms, complex arrhythmias, family history, reduced function, unusual distribution of hypertrophy, and non-ischemic scar instead shift probability toward disease. The boundary cannot be resolved by a single cutoff, because sport discipline, sex, ethnicity, body size, and years of training modify the athlete's heart. Evaluation must avoid both unjustified sports exclusion and reassurance of an arrhythmogenic phenotype misinterpreted as training adaptation.

In older adults, dyspnea and atrial fibrillation are often attributed to hypertension or aging, delaying diagnosis of ATTR amyloidosis or a late-penetrance cardiomyopathy. Coexisting aortic stenosis, coronary artery disease, renal impairment, and frailty rarely make the clinical picture monocausal. Findings such as bilateral carpal tunnel syndrome, biceps tendon rupture, lumbar spinal stenosis, neuropathy, or discordance between wall thickness and voltages increase suspicion of ATTR. A late diagnosis may retain therapeutic and familial value and should not be excluded on the basis of age alone.

In advanced heart failure, fatigue and weight loss may predominate over dyspnea because the patient is too limited to reach workloads that produce perceptible congestion. Hypotension, hyponatremia, worsening renal function, liver dysfunction, and repeated hospitalizations indicate reduced reserve even when edema is controlled. Progressive intolerance of prognostic drugs is not evidence of disease improvement but a possible marker of low output. Recognizing this phase makes it possible to discuss advanced therapies before an irreversible crisis.

Diagnostic investigations

The diagnostic pathway begins with a precise question: what abnormality is present, what common conditions could explain it, and what causes require a specific intervention. History reconstructs age at onset, progression, infections, pregnancies, medications, cancer treatment, alcohol, substances, sporting activity, and extracardiac symptoms. Family history should include at least three generations and look for heart failure, transplantation, early pacemaker implantation, sudden death, drownings, unexplained accidents, and neuromuscular diagnoses. A pedigree updated over time may reveal segregation that was not evident at the first visit.

Physical examination assesses hemodynamic status and etiologic clues. Jugular venous pressure, third or fourth heart sounds, dynamic murmurs, pulmonary congestion, hepatomegaly, ascites, and peripheral perfusion define the heart-failure profile. Variation of a murmur with Valsalva or standing may suggest dynamic obstruction, whereas pulsus paradoxus and signs of ventricular interdependence point toward pericardial disease. Macroglossia, periorbital purpura, angiokeratomas, neuropathy, and muscle weakness may carry greater diagnostic value than many untargeted tests.

The electrocardiogram may show hypertrophy, pseudoinfarction patterns, T-wave inversions, low voltages, pre-excitation, blocks, QRS fragmentation, or arrhythmias. No pattern is pathognomonic, but some combinations are highly informative: marked wall thickening with low voltages raises suspicion of amyloidosis; a short PR interval and pre-excitation with hypertrophy suggest storage diseases; early atrioventricular block with dilatation suggests laminopathy or inflammatory disease. Electrocardiographic discordance relative to echocardiography is often a positive finding that requires explanation, not a technical error.

Echocardiography measures wall thickness and volumes, identifies regional abnormalities, quantifies function and valvular disease, and assesses hemodynamics. Longitudinal strain may detect dysfunction before ejection fraction falls and may show suggestive patterns, such as relative apical sparing in amyloidosis, but it is not sufficiently specific for an isolated diagnosis. The examination must include the right ventricle, atria, pulmonary pressure, and inferior vena cava, because focusing only on left ventricular ejection fraction misses decisive components. In suspected HCM, maneuvers to provoke the gradient are necessary and, when symptoms require it, exercise echocardiography should be performed.

Cardiac magnetic resonance provides reproducible volume measurements and superior visualization of the apex, lateral wall, and right ventricle. An ischemic LGE pattern involves the subendocardium or transmural wall within a coronary territory, whereas non-ischemic patterns may be mid-wall, subepicardial, focal, or diffuse. Native T1 and extracellular volume increase with fibrosis and infiltration, whereas low T1 may suggest lipid accumulation in Fabry disease or iron; T2 identifies increased tissue water and T2* quantifies iron overload. Measurements depend on the sequence, magnetic field strength, and local reference ranges.

LGE has diagnostic and prognostic significance but should not be interpreted without context. Mid-wall scar in dilated cardiomyopathy is associated with higher arrhythmic risk and a lower probability of complete recovery, whereas extensive scar in HCM modifies the discussion regarding ICD implantation. In left-dominant arrhythmogenic cardiomyopathy, a circumferential subepicardial pattern may precede global dysfunction; in sarcoidosis, distribution is often multifocal and not confined to a coronary territory. Quantification, acquisition quality, and the underlying diagnosis determine how strongly the finding should influence a decision.

Ambulatory monitoring quantifies premature beats, nonsustained ventricular tachycardia, atrial fibrillation, and pauses. The choice among Holter monitoring, patches, mobile telemetry, and loop recorders depends on symptom frequency and the need to quantify burden, not on an abstract hierarchy of devices. A short monitor has low sensitivity for syncope occurring once a year, whereas an implantable device is excessive for daily palpitations that are easily correlated. In diseases with high electrical risk, periodic monitoring may be indicated even in the absence of symptoms.

Exercise testing assesses symptoms, capacity, blood pressure, and arrhythmias under conditions that resting examination cannot reproduce. Measurement of expired gases provides peak oxygen consumption, VE/VCO2 slope, and other indices useful for quantifying limitation and prognosis, especially in advanced heart failure. In HCM, testing may unmask provocable obstruction, whereas in arrhythmogenic forms it should be performed using protocols and surveillance consistent with the risk. Exercise prescription should derive from the overall dataset and not solely from attainment of a theoretical heart rate.

Troponin and natriuretic peptides are biomarkers of injury and stress, not etiologic tests. Mild persistent troponin elevation may occur in HCM, amyloidosis, and heart failure, whereas a dynamic increase with pain and tissue edema suggests an acute process requiring differential diagnosis from ischemia. BNP or NT-proBNP are influenced by age, renal function, rhythm, and obesity, but are useful for prognosis and serial assessment when interpreted within the same patient. Complete blood count, electrolytes, and renal, hepatic, and thyroid function identify reversible causes or limitations to therapy.

Etiologic testing should follow clinical clues. Serum and urine immunofixation with free light chains is required to exclude a monoclonal component in the workup for amyloidosis; bone-tracer scintigraphy can support a non-biopsy diagnosis of ATTR only in the appropriate context. Ferritin and transferrin saturation guide evaluation of iron overload, whereas alpha-galactosidase A, lyso-Gb3, and genetic testing are used for Fabry disease with different interpretive considerations in males and females. Autoantibodies, infectious tests, and metabolic testing should not be ordered indiscriminately because nonspecific results increase diagnostic noise.

Coronary assessment is indicated when age, symptoms, risk factors, or scar pattern make ischemic disease plausible. CCTA and coronary angiography define epicardial anatomy, whereas functional tests and invasive physiology clarify the hemodynamic relevance of stenoses. Coexisting coronary artery disease does not exclude cardiomyopathy if its distribution and severity do not explain the dysfunction or hypertrophy. Conversely, diagnosing dilated cardiomyopathy without considering ischemia in a high-risk patient creates an avoidable therapeutic error.

Genetic testing is recommended when there is a reasonable likelihood of inherited disease and the result can help the proband or family. The individual selected for testing should be the relative with the most clearly defined phenotype, not an unaffected family member, because a negative result in an unaffected person is poorly informative when the familial variant is unknown. Interpretation integrates phenotype, pedigree, and the quality of gene-disease evidence. Cascade testing is reserved for pathogenic or likely pathogenic variants and should be accompanied by counseling that explains its limitations and consequences.

Endomyocardial biopsy can diagnose giant-cell myocarditis, eosinophilic myocarditis, some storage diseases, amyloidosis, and other conditions when the result changes treatment. It is not routinely performed in stable dilated cardiomyopathy because nonspecific findings rarely alter management and sampling may miss focal lesions. Imaging or electroanatomic mapping can guide sampling in selected scenarios, increasing yield. Procedural risk is low in experienced centers but not zero and must be justified by a concrete clinical decision.

The differential diagnosis includes athlete's heart, hypertension, aortic stenosis, coronary artery disease, congenital heart disease, myocarditis, constrictive pericarditis, and adaptations to pregnancy or anemia. The magnitude of the load, its duration, and the proportionality of the cardiac response are decisive: mild hypertension does not automatically explain a very thick wall with a family history, whereas severe aortic stenosis may produce marked hypertrophy without sarcomeric cardiomyopathy. Detraining should not be used as a universal test in athletes, but may contribute in selected cases together with geometry, function, ECG, CMR, and genetics. Diagnosis remains probabilistic until all data converge.

Measurement quality precedes interpretation. Wall thickness should be measured perpendicular to the wall while avoiding trabeculae and papillary muscles; volumes should be indexed and compared with reference values appropriate to the technique; ejection fraction is affected by loading conditions, rhythm, and geometry. A change close to the reproducibility limits of the method does not prove progression. Serial imaging should, when possible, use the same modality and directly compare segments and datasets rather than relying only on reports.

Three-dimensional echocardiography and contrast address specific questions. Contrast opacifies the apex when the endocardial border is poorly defined and increases sensitivity for aneurysms and thrombi; 3D imaging improves assessment of volumes and valvular geometry when acquisition is adequate. Strain adds a measure of deformation, but depends on software and image quality and should not replace global visual and quantitative assessment. A suggestive pattern should trigger etiologic verification, not be presented as a definitive diagnosis.

T1 mapping, T2 mapping, and extracellular volume extend CMR beyond LGE. Native T1 increases with fibrosis, edema, and amyloid, decreases with lipid accumulation in Fabry disease and with iron, and must be compared with local reference ranges; T2 increases with edema but by itself does not distinguish infectious, autoimmune, or genetic inflammation. Reduced myocardial T2* indicates iron overload and quantifies its functional risk. Combining mapping with morphology and contrast enhancement generates a more informative signature than any isolated parameter.

Nuclear medicine addresses selected questions. Bone-tracer scintigraphy may permit a non-biopsy diagnosis of ATTR amyloidosis when cardiac uptake is significant and monoclonal protein testing is negative; in the presence of gammopathy, it does not adequately distinguish ATTR from AL. Fluorodeoxyglucose PET can document inflammatory activity in sarcoidosis if preparation suppresses physiological myocardial metabolism. Absent or nonspecific uptake must be compared with CMR, the clinical picture, and therapy already received.

Computed tomography is useful when CMR is contraindicated or for specific anatomical questions. CCTA excludes or defines coronary artery disease, visualizes coronary anomalies, and may contribute to procedural planning, while chest CT shows the pericardium, lungs, and systemic signs. CT delayed enhancement and extracellular volume techniques are evolving but involve radiation and iodinated contrast. The examination chosen should be the one that changes the decision with the least risk, rather than accumulating redundant modalities.

Cardiac catheterization is indicated when noninvasive hemodynamics are discordant, when restriction must be distinguished from constriction, or when transplantation, mechanical support, or a procedure is being evaluated. Simultaneous pressures, respiratory response, cardiac index, and pulmonary vascular resistance clarify mechanisms that ejection fraction does not reveal. Invasive exercise may document a pathological rise in filling pressures in patients with symptoms and inconclusive resting data. Results must be interpreted in the volume status and treatment conditions present at the time of the study.

Family screening is a diagnostic process with a pretest probability different from that of the general population. A borderline finding in a relative of a proband with a causal variant carries greater significance, but awareness of family history may also encourage overinterpretation. Electrocardiography, echocardiography, and, when indicated, CMR should be interpreted by clinicians familiar with the patient's age and genotype. Follow-up intervals and duration depend on expected penetrance and cannot be identical for all cardiomyopathies.

Genetics requires quality control even after the report has been issued. Insufficient coverage, structural variants, difficult genomic regions, and mosaicism may cause false negatives; outdated databases or weak evidence may lead to overclassification. Periodic reassessment of VUS should be performed by the laboratory or a competent service, avoiding a situation in which the patient interprets every commercial update as a clinical change. If a variant is downgraded, decisions based solely on it should be reconsidered and the family recontacted.

The final formulation should state the degree of certainty. "Dilated phenotype, probably genetic, cause not identified" conveys more information than "idiopathic," whereas "non-ischemic scar compatible with previous myocarditis" is not equivalent to proven myocarditis. Separating facts, interpretations, and alternatives reduces propagation of errors at subsequent follow-up. A diagnosis may be updated without contradicting the previous report when new evidence reasonably changes probability.

When biopsy is performed, the sample must be handled according to the suspected diagnosis. Fixation for histology, fresh or frozen material for molecular studies, and fragments for electron microscopy are not interchangeable after sampling. Immunohistochemistry quantifies and characterizes the infiltrate better than morphological impression alone, whereas special stains identify amyloid, iron, glycogen, or fibrosis. Testing for viral genomes requires rigorous methods and controls, and their presence does not necessarily prove replication or causality.

Cascade testing should be organized around a reliable familial variant. The laboratory tests relatives for that specific alteration, avoiding broad panels that would generate incidental findings and independent VUS. A positive result determines phenotype-specific surveillance, whereas a negative result reduces risk related to that variant but does not explain independent symptoms or findings. Relatives should be informed while respecting confidentiality and autonomy, with tools that help the proband communicate without transferring the entire clinical responsibility to them.

Automated analysis algorithms can quantify volumes, strain, scar, and electrocardiographic patterns, but their performance depends on the training data and disease prevalence. A model that is accurate in a specialist center may generate many false positives in population screening. Artificial intelligence can select patients for evaluation and improve reproducibility, but it does not replace clinical and etiologic confirmation. Transparency, external validation, and error assessment across subgroups are requirements before use in decision-making.

Treatment and prognosis

Treatment begins with correction of reversible causes and removal of aggravating factors. Control of tachyarrhythmia, alcohol abstinence, withdrawal or substitution of a cardiotoxic agent, treatment of endocrine disorders, and correction of deficiencies can produce substantial recovery, especially before extensive scar develops. Reversibility should not, however, be assumed: the patient simultaneously requires therapy appropriate to the hemodynamic phenotype. When an acquired factor and genetic predisposition coexist, removing the exposure reduces risk but does not eliminate the need for familial and cardiological follow-up.

Treatment of reduced ejection fraction includes, in appropriate patients, an ARNI or renin-angiotensin system inhibition, a beta-blocker with evidence in heart failure, a mineralocorticoid receptor antagonist, and an SGLT2 inhibitor. These classes act on complementary pathways and should be introduced early at tolerated doses, without necessarily waiting for maximal titration of one class before starting the others. Blood pressure, heart rate, potassium, and renal function guide sequencing. Diuretics correct congestion but do not replace disease-modifying therapy.

Improved function is defined relative to the baseline value and does not automatically justify treatment withdrawal. In dilated cardiomyopathy in remission, the TRED-HF trial documented a high frequency of relapse after gradual withdrawal of therapy, demonstrating persistence of the substrate in many patients. Surveillance should include symptoms, imaging, rhythm, and biomarkers, because recurrence may initially be silent. Exceptional dose reductions for hypotension, pregnancy, or adverse effects must be individualized and should not be interpreted as evidence of cure.

In forms with preserved ejection fraction, treatment depends on the mechanism. Careful use of diuretics reduces congestion, rate control prolongs filling when tachycardia is unfavorable, and comorbidities such as hypertension, obesity, diabetes, and obstructive sleep apnea should be treated. A restrictive or obstructive ventricle may depend critically on preload, making excessive diuresis dangerous. General evidence in heart failure with preserved ejection fraction should be applied while accounting for the specific features of cardiomyopathies that were excluded or underrepresented in trials.

In obstructive HCM, nonvasodilating beta-blockers are often the first choice to reduce heart rate, contractility, and gradient; verapamil or diltiazem are alternatives in appropriate settings, whereas disopyramide may be added in experienced centers. Mavacamten reduces actin-myosin interaction and may improve gradient and symptoms in selected patients, but requires ejection-fraction monitoring and management of drug interactions. Severe symptoms with a gradient of at least 50 mmHg despite adequate therapy warrant evaluation for myectomy or alcohol septal ablation. The choice depends on anatomy, mitral pathology, age, comorbidities, and center experience.

Atrial fibrillation is treated with rate or rhythm control according to symptoms, duration, atrial size, and hemodynamic tolerance. Cardioversion, drugs, and ablation may be necessary, recognizing that recurrence is more common when atrial remodeling and filling pressures are marked. In HCM, anticoagulation is indicated for clinical atrial fibrillation regardless of CHA2DS2-VASc score, unless contraindicated, because disease-specific embolic risk is high. In other cardiomyopathies, general indications are applied together with consideration of thrombi, aneurysms, function, and embolic history.

Ventricular arrhythmias are managed by correcting precipitating factors, drugs, ablation, and ICD therapy. Amiodarone may reduce recurrences but has cumulative toxicities; sotalol and other drugs are selected according to ventricular function, QT interval, and substrate. Ablation is particularly complex in arrhythmogenic forms because circuits may be epicardial and disease may progress beyond the treated areas. Procedural success reduces tachycardia and shock burden, but does not replace an ICD when the indication for sudden-death prevention persists.

An ICD is indicated for secondary prevention after cardiac arrest or hemodynamically not tolerated sustained ventricular tachycardia not due to a reversible cause; in hemodynamically tolerated sustained ventricular tachycardia, the indication should be individualized. For primary prevention, the decision varies by phenotype: disease-specific models and factors in HCM, ejection fraction and scar in DCM, genotype and arrhythmic burden in arrhythmogenic forms, and involvement and inflammation in sarcoidosis. Age, comorbidities, and the probability of non-arrhythmic death modify the absolute benefit. In young patients, decades of generator replacements, infections, malfunctions, and inappropriate shocks must be considered without underestimating substantial arrhythmic risk.

Pacemakers and cardiac resynchronization therapy address different problems. A pacemaker corrects bradycardia and block, but a high percentage of right ventricular pacing may worsen function in a vulnerable heart; the initial device choice should therefore anticipate pacing requirements. CRT improves symptoms and prognosis in patients with dysfunction, a wide QRS, and dyssynchrony who meet criteria, and may be considered in specific situations with anticipated pacing. The presence of cardiomyopathy does not replace electrocardiographic and functional indications, but some genotypes make progression of conduction disease more likely.

Etiology-specific therapies have changed the prognosis of some diseases. Tafamidis stabilizes transthyretin in ATTR cardiomyopathy in selected patients, whereas transthyretin synthesis silencers have evolving indications and evidence according to phenotype and regulatory authorization. AL amyloidosis requires rapid suppression of the plasma-cell clone in collaboration with hematology; Fabry disease may be treated with enzyme replacement therapy or migalastat in amenable variants; iron overload requires phlebotomy or chelation according to its cause. Benefit is greater before organ damage becomes irreversible.

Immunosuppression is not a generic treatment for inflammatory cardiomyopathy. It is indicated in defined conditions, such as giant-cell myocarditis, clinically active cardiac sarcoidosis, and some eosinophilic or immune-mediated forms, after evaluation demonstrates a favorable benefit-risk balance. In unselected lymphocytic myocarditis, imaging evidence of inflammation is not sufficient to prescribe corticosteroids indiscriminately. Identification of infectious agents and the immunological context are necessary because suppressing the immune response may be ineffective or harmful in some scenarios.

Physical activity is prescribed according to symptoms, function, arrhythmias, obstruction, scar, genotype, and type of sport. Moderate aerobic exercise is generally beneficial and should not be withheld without reason, whereas high volumes of endurance exercise are discouraged in arrhythmogenic cardiomyopathies because of their effect on progression. Decisions about competitive sports require shared assessment and periodic reassessment, recognizing that no strategy completely eliminates risk. Patients should know warning symptoms and the circumstances in which activity should be stopped.

Pregnancy and contraception require planning. Ventricular function, previous heart failure, obstruction, arrhythmias, pulmonary pressure, and therapy determine maternal risk, whereas genotype informs the possibility of transmission without necessarily predicting severity in the child. Teratogenic drugs must be discontinued or replaced with adequate timing, balancing fetal risk and maternal stability. A cardio-obstetric team defines follow-up frequency, mode and place of delivery, and postpartum management, a period in which changes in volume may precipitate heart failure.

Mechanical ventricular support is more readily applicable to dilated ventricles with systolic failure than to small restrictive cavities, in which chamber size and right ventricular dysfunction create technical and hemodynamic difficulties. Transplantation is indicated in refractory heart failure, intractable ventricular arrhythmias, or severe unmodifiable limitation, after assessment of comorbidities and systemic involvement. Late referral increases the risk of irreversible pulmonary hypertension, malnutrition, and renal or hepatic failure. Advanced heart-failure centers should be involved before all conventional options have been exhausted in a critical condition.

Prognosis cannot be expressed as a single value for all cardiomyopathies. Recovery of function, rhythm stability, absence of extensive scar, and response to therapy are favorable, whereas high-risk genotypes, biventricular dysfunction, LGE, arrhythmias, pulmonary hypertension, and multiorgan involvement worsen outcomes. Modern cohorts treated in experienced centers often show better survival than historical series, but referral bias may act in both directions. Accurate communication distinguishes the risks of heart failure, arrhythmic death, embolism, and systemic progression, because each requires different preventive strategies.

Initiation of heart-failure therapy should prioritize how quickly the patient receives all foundational drug classes at tolerated doses. Waiting months to maximize a single drug prolongs exposure to untreated neurohormonal pathways; on the other hand, starting multiple drugs without a monitoring plan may cause hypotension, hyperkalemia, or worsening renal function. Close visits, laboratory testing, and instructions regarding blood pressure, weight, and symptoms permit safe titration. A modest initial change in filtration does not always require discontinuation if congestion, potassium, and the overall trend remain controlled.

Chronic congestion requires distinguishing total volume from its distribution. A patient with high filling pressures may not have marked edema, whereas another has peripheral edema aggravated by venous insufficiency or hypoalbuminemia. Loop diuretics, sequential nephron blockade, and sodium and fluid management are tailored to the individual; excessive uniform restriction is not necessary for everyone. Monitoring should prevent both residual congestion and hypovolemia, which is particularly dangerous in obstructive or restrictive physiology.

Etiology-specific therapy for amyloidosis requires certain typing. In AL, the speed of hematologic response is crucial, but drugs must be tolerated by a vulnerable heart; in ATTR, transthyretin stabilization reduces its amyloidogenic dissociation, whereas silencing reduces its production; both strategies slow new deposition without immediately removing existing material. A monoclonal gammopathy in an older adult does not prove AL, and a positive scintigraphy result in its presence is not sufficient for ATTR. Typing errors expose patients to ineffective treatments and delay therapy for a time-dependent disease.

In Fabry disease, enzyme replacement therapy and chaperone therapy for amenable variants target the metabolic defect, but advanced fibrosis reduces the likelihood of cardiac recovery. Heterozygous women may have enzyme activity within the normal range because of random X-chromosome inactivation and require genetic confirmation. In glycogen storage and mitochondrial diseases, treatment involves metabolism, nutrition, neurology, and arrhythmia management. Diagnostic precision prevents every case of hypertrophy with pre-excitation from being regarded as sarcomeric HCM.

Arrhythmia control must include treatment of the hemodynamic substrate. Correcting congestion, ischemia, electrolyte abnormalities, sleep apnea, and hyperthyroidism reduces triggers and improves the effectiveness of drugs or ablation. Antiarrhythmic selection takes ventricular function, scar, QT interval, conduction, and interactions into account, because agents that are safe in a normal heart may become proarrhythmic in cardiomyopathy. In patients with electrical storms, sedation, sympathetic modulation, ablation, and circulatory support may be required within a coordinated pathway.

Anticoagulation is not indicated solely for ventricular dilatation in sinus rhythm without thrombus or another indication, because embolic benefit does not consistently outweigh bleeding risk. It becomes necessary in atrial fibrillation according to context, intracardiac thrombus, prosthetic valves, or embolic events with a demonstrated mechanism. An apical aneurysm or severe stasis requires individual discussion when evidence does not define a universal rule. Drug and dose must be adapted to renal function, body weight, age, and interactions.

The choice between a transvenous ICD and a subcutaneous ICD depends on the anticipated need for pacing, resynchronization, and antitachycardia pacing. The subcutaneous system avoids intravascular leads but does not treat bradycardia or deliver antitachycardia pacing; the transvenous system offers more functions at the cost of endovascular risks. Sensing testing, venous anatomy, age, and arrhythmic history contribute to the decision. Programming with appropriate zones and detection times reduces inappropriate shocks without forgoing treatment of dangerous arrhythmias.

Nutrition and rehabilitation should avoid both generic prescriptions and loss of body mass. Obesity increases hemodynamic load, atrial fibrillation, and procedural difficulty, but in advanced disease rapid weight loss may indicate congestion or cachexia rather than dietary success. Adapted aerobic and resistance training preserves peripheral function, while sodium, alcohol, and supplements are assessed in relation to the cause and medications. Herbal products and stimulants may interact or promote arrhythmias and should be specifically investigated.

Care planning includes education about warning symptoms, adherence, travel, fever, dehydration, and non-cardiac procedures. Anesthesia and surgery alter preload, afterload, and rhythm and require precise information about the phenotype, especially in severe obstruction, amyloidosis, and conduction disease. A concise document listing diagnosis, devices, medications, and referral-center contacts reduces errors in emergencies. Patient participation is a component of safety, not simply a measure of satisfaction.

When disease becomes advanced, hospitalizations, peak oxygen consumption, ventilatory slope, hypotension, right ventricular function, pulmonary pressures, and organ injury are integrated into treatment selection. No single cutoff determines transplantation or mechanical support, and general prognostic models may be less accurate in hypertrophic or restrictive physiology. Early evaluation makes it possible to correct frailty and reversible conditions, assess donor-related issues, and discuss preferences. Palliative care may accompany advanced therapies and should not be deferred until the terminal stage.

Percutaneous or surgical valvular procedures are considered only after defining the relationship between valve and ventricle. In functional mitral regurgitation associated with DCM, optimization of medical therapy and resynchronization may reduce regurgitation; persistent severe regurgitation in selected patients may make transcatheter repair useful. In HCM, treating the leaflet alone without correcting the septum and subvalvular apparatus may leave obstruction unresolved. The Heart Team and cardiomyopathy center should share imaging and goals before the procedure.

Remote monitoring of weight, blood pressure, rhythm, and devices may anticipate arrhythmias or deterioration, but more data do not guarantee benefit if there is no response pathway. Thresholds that are too sensitive generate alerts and fatigue, while nonintegrated systems duplicate work and confuse patients. Telemedicine is most effective when it defines who reviews the data, within what timeframe, and with what actions. It does not replace examination and imaging when physical or tissue assessment is needed.

Molecular therapies, gene editing, oligonucleotides, and modulation of contractile proteins are expanding precision medicine, but evidence remains specific to the gene, mechanism, and disease stage. Reducing a toxic protein may be useful in a dominant-negative mechanism and harmful in haploinsufficiency; correcting a defect after advanced fibrosis may not restore lost tissue. Participation in a trial requires robust molecular confirmation, clinically meaningful endpoints, and follow-up for late effects. Biological enthusiasm should not precede demonstrated safety and benefit.

Complications

Heart failure is the final convergence of many mechanisms. In dilated forms, reduced contractility, increased volumes, and functional valvular regurgitation predominate; in hypertrophic forms, stiffness, microvascular ischemia, and sometimes obstruction dominate; in restrictive forms, high pressures result from reduced distensibility with non-dilated cavities. Ejection fraction does not measure effective cardiac output or filling pressures and may remain normal in severe disease. The complication must therefore be defined through clinical status, hemodynamics, and biventricular function.

An acute decompensation may be precipitated by infection, arrhythmia, ischemia, anemia, thyroid dysfunction, excess sodium, medications, pregnancy, or nonadherence. Identifying the precipitant is part of treatment because diuresis alone may produce temporary improvement followed by renewed instability. In preload-dependent cardiomyopathies, excessive volume reduction causes hypotension and worsening renal function. Management requires a narrower hemodynamic window than that observed in many common forms of heart failure.

Cardiogenic shock results from cardiac output insufficient to maintain perfusion and may occur because of systolic deterioration, arrhythmia, fulminant myocarditis, severe obstruction, or acute valvular regurgitation. Phenotype and cause determine the choice among inotropes, vasopressors, and mechanical support, because increasing contractility may worsen obstruction in HCM. Early evaluation for temporary support or transplantation is essential in potentially reversible cases or transplant candidates. Delay allows multiorgan injury to turn a recoverable condition into a contraindication to advanced therapies.

Atrial fibrillation reduces the atrial contribution to filling, shortens diastole, and increases embolic risk. It is particularly destabilizing in stiff ventricles and may cause a sudden loss of functional capacity or pulmonary edema. Atrial dilatation and fibrosis promote recurrence, making maintenance of sinus rhythm progressively more difficult. Early diagnosis, appropriate anticoagulation, and a rhythm- or rate-control strategy should be integrated before atrial remodeling becomes advanced.

Ventricular tachycardia and ventricular fibrillation are the main mechanisms of sudden death. Scar and disarray create heterogeneous conduction, while ischemia, inflammation, and adrenergic stimulation may act as triggers. Risk may be significant even with moderately reduced or preserved ejection fraction in HCM, laminopathies, and arrhythmogenic phenotypes. Reliance on a single ventricular-function threshold would therefore miss vulnerable patients, but indiscriminate expansion of ICD use would expose many individuals to complications without certain benefit.

Bradyarrhythmias include sinus node dysfunction, atrioventricular block, and intraventricular conduction disease. They may be a primary manifestation of LMNA, DES, SCN5A, sarcoidosis, amyloidosis, or neuromuscular dystrophies and may precede mechanical dysfunction. Syncope, pauses, and progression of PR or QRS intervals require monitoring and timely device selection. In phenotypes at ventricular arrhythmic risk, implanting a simple pacemaker without considering a defibrillator may necessitate a subsequent complex revision.

Thromboembolism may originate in the atria during atrial fibrillation or severe atrial myopathy, from ventricular thrombi in dilated hypokinetic cavities, or from apical aneurysms. Stroke and peripheral emboli may precede recognition of cardiomyopathy. Contrast imaging increases sensitivity for apical thrombi, whereas prolonged monitoring may identify silent atrial fibrillation. Anticoagulation is guided by mechanism and bleeding risk, not merely by the presence of reduced ejection fraction.

Mitral regurgitation in dilated cardiomyopathy results from annular enlargement, papillary muscle displacement, and leaflet tethering; in obstructive HCM, systolic anterior motion produces a regurgitant jet often directed posteriorly. These mechanisms require different solutions and accurate echocardiographic description. Tricuspid regurgitation follows right-sided dilatation, increased pulmonary pressures, or the presence of transvenous leads. Progression of valvular regurgitation increases congestion and reduces the likelihood of favorable remodeling.

Pulmonary hypertension is initially post-capillary and results from chronically elevated left atrial pressure. Over time, a pre-capillary vascular component may develop, increasing right ventricular afterload and transplantation risk until it becomes poorly reversible. Echocardiography estimates probability, whereas right-heart catheterization defines pressures and resistance when the result changes therapy or candidacy. The right ventricle is an independent prognostic determinant and should not be considered merely a late victim of left-sided disease.

Recurrent inflammation may cause episodes of pain, troponin elevation, and new areas of scar, especially in some genetic cardiomyopathies. Each episode may increase the arrhythmic substrate and may be misclassified as isolated myocarditis, interrupting diagnostic continuity. Serial CMR, family history, and genetic testing help recognize the pattern. Failure to demonstrate a virus does not automatically prove an autoimmune process, just as an intercurrent infection does not prove causality.

Extracardiac involvement may cause complications independent of cardiac function. Nephropathy in Fabry disease and amyloidosis, autonomic neuropathy, liver disease, respiratory muscle weakness in dystrophies, and mitochondrial diabetes influence medications, devices, anesthesia, and transplant candidacy. Treating the heart without following the systemic disease produces incomplete improvement and may expose the patient to avoidable risks. Multidisciplinary management is particularly important when etiology-specific therapies affect different organs differently.

Devices have their own complications: infection, hematoma, pneumothorax, perforation, lead malfunction, inappropriate shocks, and psychological harm. In children and young adults, cumulative risk increases with the number of replacements and revisions, whereas subcutaneous systems avoid transvenous access but do not provide antitachycardia or antibradycardia pacing. Device selection should anticipate future needs for pacing, resynchronization, and venous access. A technically successful implantation does not complete the preventive pathway.

End-stage progression includes cardiac cachexia, renal and hepatic failure, hyponatremia, frailty, and reduced ability to tolerate therapies. These signs should not be awaited before referral to an advanced heart-failure center, because they reduce options and increase waiting-list mortality. Palliative care and symptom control should be integrated when transplantation or mechanical support are not possible, without being equivalent to abandonment of care. Early discussion of goals enables coherent decisions before a crisis occurs.

Psychological and familial consequences are part of the disease. The risk of sudden death, uncertainty surrounding a VUS, sports restrictions, and the possibility of transmission may cause anxiety, hypervigilance, or conflict among relatives. Poorly calibrated communication may lead to occupational exclusions and harmful sedentary behavior, whereas minimizing risk undermines adherence. Genetic counseling, psychological support, and shared decision-making help translate complex information into proportionate behavior.

Electrical storm, defined by closely recurring treated ventricular arrhythmias, is an extreme medical and psychological complication. Ischemia, heart failure, infection, electrolyte disturbances, and drugs may precipitate it on a scar substrate; repeated shocks increase sympathetic activation and may perpetuate the cycle. Intensive management combines correction of triggers, antiarrhythmic drugs, sedation, device programming, ablation, and sometimes autonomic modulation. Mechanical support may stabilize patients in whom instability prevents an effective procedure.

Renal dysfunction may result from low cardiac output, venous congestion, medications, or shared systemic disease. Renal congestion reduces filtration even with preserved arterial pressure and may improve with effective decongestion, whereas hypovolemia and hypotension produce a different mechanism. Congestive hepatopathy progresses from elevated right-sided pressures to fibrosis and, in prolonged cases, cardiac cirrhosis. Distinguishing reversible functional injury from structural disease is essential in transplant evaluation.

Sudden death does not always leave diagnostic morphology. Electrical phases or microscopic scars may escape a nonspecialist autopsy, and the absence of gross abnormalities does not exclude familial cardiomyopathy. Standardized sampling of both ventricles, toxicology, review of circumstances, and DNA preservation increase diagnostic yield. Relatives should undergo clinical evaluation even when molecular autopsy is negative, because an uninformative genetic result is not equivalent to absence of inherited disease.

Pregnancy may be complicated by heart failure, arrhythmias, thromboembolism, preterm delivery, and persistent worsening of function. Risk is greater with reduced ejection fraction, previous events, severe obstruction, pulmonary hypertension, and advanced functional class, but changes during pregnancy and the postpartum period. Medications discontinued for fetal safety may reduce maternal protection and require alternatives and monitoring. Emergency management must simultaneously balance maternal and fetal perfusion, with maternal stabilization taking priority.

In children, growth failure and developmental delay may result from low cardiac output, increased work of breathing, malabsorption, or syndromic disease. Hospitalizations and devices interfere with school, social life, and body image, while parents face both transmission risk and risk to other children. Doses and indications cannot be automatically extrapolated from adults, and ICD decisions must account for growth and future revisions. Planned transition to adult cardiology prevents loss to follow-up during a period of increasing autonomy.

Iatrogenic complications also arise from appropriate therapies. Diuretics may cause hypovolemia, neurohormonal drugs hypotension and electrolyte abnormalities, antiarrhythmics organ toxicity, anticoagulants bleeding, and procedures valvular injury or block. An adverse event does not prove that the indication was wrong, but requires reassessment of dose, alternatives, and absolute benefit. Follow-up capable of recognizing these problems early preserves therapeutic benefit while avoiding indiscriminate discontinuation.

Infections are particularly important in patients with devices, transplant recipients, and immunosuppressed patients. Bacteremia may seed transvenous leads and require complete extraction, while immunosuppression modifies presentation and response. Vaccination, procedural hygiene, and timely treatment reduce risks that can destabilize even compensated cardiomyopathy. Fever increases heart rate and metabolic demand and may unmask limited reserve before localizing signs appear.

Familial progression has cumulative consequences: several members may require follow-up, devices, or care at the same time, with economic and organizational impact. A molecular diagnosis clarifies who requires surveillance but may also generate perceived discrimination and insurance difficulties depending on the regulatory context. The team should provide understandable documentation and distinguish potential risk from current functional limitation. Familial prevention is effective when it preserves social participation as well as reducing clinical events.